• Roshni Pushpa Raghavan
  • Aiswarya Purushothaman
  • Ginil Kumar
  • Gangadharan P


Objective: Prostate cancer is the most common visceral malignancy and leading cause of cancer‑related death in men. Androgen deprivation therapy
is the established treatment of metastatic prostate cancer and has different approaches in the reduction of androgen activity including surgical
castration (bilateral orchiectomy) and medical castration (luteinizing hormone‑releasing hormone agonists/antagonists). Our purpose was to study
the clinical profile, effectiveness, and outcome of South Indian patients with metastatic prostate cancer undergoing treatment with surgical and
medical castration.
Methods: A total of 30 surgical and 30 medical castration patients diagnosed with metastatic prostate cancer between (2008 and 2009) were followed
up to 5 years. Serum prostate specific antigen (PSA) levels at the time of the first diagnosis, post‑treatment nadir PSA levels, time to nadir PSA, time
to hormonal resistance between the study groups were assessed, retrospectively. The Kaplan–Meier method was used with log‑rank test for survival
rate calculations. Gleason score, PSA levels, skeletal‑related events, and sites of metastasis of the study groups were studied.
Result: The average survival time after medical castration was 60 months and 42 months for surgical castration. No significant difference could be
established between the groups. Bone was the most common site of metastasis and radiation was the major skeletal‑related events in medical groups.
Conclusion: There were no statistical differences between the groups in terms of treatment modalities in metastatic prostate cancer.
Keywords: ???


1. Jain S, Saxena S, Kumar A. Epidemiology of prostate cancer in India.
Meta Gene 2014;2(9):596‑605.
2. Keating NL, O’Malley AJ, McNaughton‑Collins M, Oh WK,
Smith MR. Use of androgen deprivation therapy for metastatic prostate
cancer in older men. BJU Int 2008;101(9):1077‑83.
3. Carson AP, Howard DL, Carpenter WR, Taylor YJ, Peacock S,
Schenck AP, et al. Trends and racial differences in the use of androgen
deprivation therapy for metastatic prostate cancer. J Pain Symptom
Manage 2010;39(5):872‑81.
4. Connolly RM, Carducci MA, Antonarakis ES. Use of androgen
deprivation therapy in prostate cancer: Indications and prevalence.
Asian J Androl 2012;14(2):177‑86.
5. Gandaglia G, Karakiewicz P, Sun M. Beyond the bone: Atypical
metastases in prostate cancer. Cancer Cell Microenviron
6. Auclerc G, Antoine EC, Ajfinger FC, Cajfinger F, Brunet‑Pommeyrol A,
Khayat D, et al. Management of advanced prostate cancer. Oncologist
7. Bayraktar S, Wahab MA. Current medical and surgical options for
androgen deprivation in prostate cancer patients. Open Prostate Cancer
J 2010;2(3):55‑8.
8. Abouelfadel Z, Crawford ED. Leuprorelin depot injection: Patient
considerations in the management of prostatic cancer. Ther Clin Risk
Manag 2008;4(2):513‑26.
9. Akinremi TO, Ogo CN, Olutunde AO. Review of prostate cancer
research in Nigeria. Infect Agent Cancer 2011;6(2):10‑8.
10. Hotte SJ, Saad F. Current management of castrate‑resistant prostate
cancer. Curr Oncol 2010;17 Suppl 2:S72‑9.
11. Clarke JM, Armstrong AJ. Novel therapies for the treatment of advanced
prostate cancer. Curr Treat Options Oncol 2013;14(1):109‑26.
12. Pourmand G, Salem S, Mehrsai A, Lotfi M, Amirzargar MA, Mazdak H,
et al. The risk factors of prostate cancer: A multicentric case‑control
study in Iran. Asian Pac J Cancer Prev 2007;8(3):422‑8.
13. Leitzmann MF, Rohrmann S. Risk factors for the onset of prostatic
cancer: Age, location, and behavioral correlates. Clin Epidemiol
14. Singh S, Raguvaran R, Rajkumar K. Factors influencing prostate
cancer. Int J Pharm Sci 2014;6:33‑5.
15. Kolonel LN. Fat, meat, and prostate cancer. Epidemiol Rev
16. Ganesh B, Saoba SL, Sarade MN, Pinjari SV. Risk factors for prostate
cancer: An hospital‑based case‑control study from Mumbai, India.
Indian J Urol 2011;27(3):345‑50.
17. Martel CL, Gumerlock PH, Meyers FJ, Lara PN. Current strategies in
Purushothaman et al.
the management of hormone refractory prostate cancer. Cancer Treat
Rev 2003;29(3):171‑87.
18. Gandaglia G, Karakiewicz PI. Maxine sun beyond the bone:
Atypical metastases in prostate cancer. Cancer Cell Microenviron
19. Winer AG, Sfakianos JP, Hyacinthe LM, McNeil BK. A 10‑year
analysis of metastatic prostate cancer as an initial presentation in an
underserved population. Int Braz J Urol 2014;40(3):30‑41.
20. Demir A, Cecen K, Karadag MA, Kocaaslan R, Turkeri L. The course
of metastatic prostate cancer under treatment. Springerplus 2014;3:725.
Asian J Pharm Clin Res, Vol 9, Issue 2, 2016, 51-54
21. Botto H, Rouprêt M, Mathieu F, Richard F. Multicentre randomized
trial comparing triptorelin medical castration versus surgical castration
in the treatment of locally advanced or metastatic prostate cancer. Prog
Urol 2007;17(2):235‑49.
22. Yang C, Qi GS, Rong RM, He J. Clinical features and treatment
strategies for older prostate cancer patients with bone metastasis. Asian
J Androl 2013;15(6):759‑63.
23. Broder MS, Gutierrez B, Cherepanov D, Linhares Y. Burden of
skeletal‑related events in prostate cancer: Unmet need in pain
improvement. Support Care Cancer 2015;23:237‑47.
362 Views | 681 Downloads
How to Cite
Raghavan, R., A. Purushothaman, G. Kumar, and G. P. “A COMPARISON OF LEUPROLIDE ACETATE VERSUS BILATERAL ORCHIECTOMY FOR PATIENTS WITH METASTATIC PROSTATE CANCER”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 9, no. 2, Mar. 2016, pp. 51-54, https://innovareacademics.in/journals/index.php/ajpcr/article/view/8255.
Original Article(s)